Innovations in Blood
Biomarker Discovery

Welcome to Sangui Bio

Innovating whole-blood proteomics with VeriPro, our biomarker discovery platform.

The platform

From a single drop of blood to a biomarker panel.

The VeriPro platform pairs at-home microsampling with whole-blood proteomics. Biomarkers correlated with gold-standard reference tests become diagnostics conducted on a simple at-home fingerprick blood sample.

At-home fingerprick collection device
1 · Microsampling

At-home blood collection

A single 30 µL fingerprick whole-blood sample. No clinic visit, no prep, no fasting – mailed back at ambient temperature.

Reference disease test illustration
2 · Reference test

Gold-standard screening

Participants undergo the gold-standard screening disease test – colonoscopy, mammogram or CT – providing the clinical data needed to enable biomarker discovery.

Mass spectrometry instrument
3 · Proteomics

Whole-blood mass spectrometry

Samples are processed with Sangui Bio's proprietary preparation methods and analysed by mass spectrometry, identifying and quantifying ~4,000 proteins per sample.

Protein analysis visualisation
4 · Biomarker panels

Diagnostic classifier

Machine learning models are trained on the proteomics data to select a focused biomarker panel that classifies disease status, enabling a blood-based diagnostic from an at-home collected sample.

Introducing ColoPro

Our lead product: A blood test for colorectal precancerous polyp detection.

ColoPro at-home collection kit
The test

ColoPro is the lead diagnostic developed on VeriPro: a blood test for colorectal precancerous polyps in high-risk patients in the surveillance cohort. It detects advanced precancerous polyps from a 30 µL fingerprick blood sample collected at home.

The unmet need

The target population is 25 million Americans who have had polyps removed and need ongoing surveillance, a group with no approved blood-based alternative today.

In practice

Annual testing, ordered by the gastroenterologist, will return a risk score that enables high-risk patients to be prioritised for follow-up colonoscopy.

Learn more about ColoPro
Why early detection matters

Colorectal cancer is the second leading cancer killer, yet 99% preventable by removing polyps early.

Polyps found during routine surveillance are removed before cancer develops. ColoPro is designed to detect advanced precancerous polyps from an at-home blood sample.

Clinical and scientific foundation

Built on a decade of proteomics research, biomarker discovery and technology development.

Sangui Bio operates from the Kolling Institute at Royal North Shore Hospital, a partnership between the Northern Sydney Local Health District and the University of Sydney. The work is grounded in foundational discoveries about blood biochemistry, across a decade of intellectual property development and peer-reviewed research. The company is now establishing a Clinical and Scientific Advisory Board, with Professor Uri Ladabaum of Stanford University as inaugural member, to guide its clinical development.

0
Peer-reviewed publications (2018–2026)
0
Patent families. US granted, international pending
0
Years of medical research at the Kolling Institute
Partner with us

Working with clinicians, researchers, and investors.

Sangui Bio is raising to advance ColoPro through clinical validation. We work with gastroenterology practices, clinical research partners, and strategic investors.